|
|
||||||||
1Department of Biomedical Sciences, Center for Gender Physiology and Environmental Adaptation, 2Veterinary Pathobiology, and 3Dalton Cardiovascular Research Center, University of Missouri, Columbia, Missouri 65211
Submitted 15 March 2004 ; accepted in final form 6 July 2004
| ABSTRACT |
|---|
|
|
|---|
voltage clamp; vascular; voltage-gated calcium channels
Sex hormones exert multifaceted effects on vascular reactivity. Whereas many vascular effects of sex hormones are endothelium mediated (13, 16, 43), considerable evidence implicates vascular smooth muscle as a target. Acute administration of both estrogen and testosterone has been shown to relax arterial preparations in vitro (8, 9, 11). Similarly, acute administration of testosterone has been shown to increase anginal threshold in men with CHD (40). The acute relaxation effect of testosterone is due, in part, to the effects on smooth muscle ion channel activity; in particular, activation of large-conductance Ca2+-activated K+ channels (11, 39, 44) and inhibition of L-type Ca2+ channels (38). Thus ion channels contribute to many acute, presumably nongenomic, effects of sex hormones on vascular smooth muscle.
Fewer and more equivocal studies exist regarding long-term, potentially genomic, effects of testosterone on the vasculature. Khalil and colleagues (9, 10, 34) found that KCl-induced contraction and Ca2+ influx was greater in thoracic aortas of male rats compared with females, suggesting a greater voltage-gated calcium channel (VGCC) activity in males. This sex difference was eliminated by ovariectomy in females and restored with estrogen; in males, castration had no effect. These findings led to the conclusion that estrogen, not testosterone, is the primary sex hormone modulating vascular smooth muscle VGCC activity. However, in swine, chronic exogenous testosterone administration increased KCl-induced contractile responses of coronary arteries in both males and females (12). Similarly, canine coronary artery contractions to U46619
[GenBank]
were reported to be greater in males compared with females, a difference which was eliminated by antiandrogens (24). Thus the role of testosterone in modulating vascular smooth muscle VGCCs in large mammals is unclear. Recently, we reported an increased L-type voltage-gated Ca2+ current (ICa,L) in coronary arterial smooth muscle (CASM) of male swine compared with females (3). Sequencing of the 5'-untranslated region of the
-subunit of the L-type VGCC (Cav1.2) gene provides evidence for a hormone response element activated by testosterone (27) suggesting that testosterone could regulate Cav1.2 gene expression and protein levels in vivo and thus contribute to gender differences in VGCC activity. Thus the purpose of the present study was to determine whether endogenous testosterone regulates ICa,L through regulation of VGCC expression and activity in CASM.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Castration and hormone replacement. Castration (orchiectomy) and hormone replacement was performed by the Swine Hormone Core within the Center for Gender Physiology and Environmental Adaptation, University of Missouri. One week after arrival, sexually mature animals (6 to 7 mo of age) were castrated with aseptic techniques under sedation with xylazine (15 mg/kg im) and ketamine (2.5 mg/kg im) and maintained under anesthesia with 1.52.0% isoflurane. Males were castrated (CM) via an incision made through the scrotum over each testicle (intact males; IM) and subsequently randomized to receive testosterone replacement (CMT; Androgel, Solvay Pharmaceuticals, 10 mg/day) or vehicle. Testosterone replacement occurred at the time of castration to avoid disruption of hormonal influence. Females remained gonad intact. Animals were euthanized for study 56 wk after surgery.
Hormone assays. Blood samples (5 ml) were collected at the time of surgery before castration and at the time of death. Samples were collected into plain tubes and centrifuged at 1,000 rpm for 5 min, and the serum was decanted and frozen at 80°C until analysis. Testosterone was determined with a commercially available RIA kit (Diagnostic Products; Los Angeles, CA). Essentially, a solid-phase 125I-labeled RIA was utilized with a sensitivity of 4 ng/dl and an interassay and intraassay coefficient of variation of 8% and 6%, respectively. Cross-reactivity studies to the antibody established that the RIA was specific for testosterone with only 19-nortestosterone having 20% and 11-ketotestosterone with 16% cross-reactivity. Parallelism studies were also carried out with pooled boar serum, both at the high and low ends of the standard curve, resulting in good linearity.
Preparation of coronary arteries. At the time of death, animals were anesthetized with ketamine (30 mg/kg im) and pentobarbital sodium (35 mg/kg iv) and administered heparin. The hearts were removed and placed in Krebs bicarbonate solution (4°C) during vessel isolation. Conduit (>1.0 mm inner diameter) segments of the right coronary artery (RCA) were trimmed of fat and connective tissue in sterile modified Eagle's minimal essential storage media containing 20 mM HEPES on ice.
CASM cell isolation.
Freshly dispersed CASM cells were obtained as described previously (3, 5, 6, 18). RCA were opened longitudinally and pinned, lumen side up, onto a silicone rubber substratum in
2 ml of low-Ca2+ solution. Cells were dispersed by incubation in enzyme solution consisting of low-Ca2+ (0.1 mM) physiological solution plus 294 U/ml collagenase (CLS II, Worthington), 6.5 U/ml elastase (Worthington), 2 mg/ml bovine serum albumin (fraction V, Sigma), 1 mg/ml soybean trypsin inhibitor (type I-S, Sigma), and 0.4 mg/ml DNase I (type IV, Sigma) for 60 min in a water bath at 37°C. The enzyme solution was then replaced with enzyme-free low-Ca2+ solution, and isolated single cells were obtained by repeatedly directing a stream of low-Ca2+ solution over the artery via a fire-polished Pasteur pipette. Cell suspensions were stored in low-Ca2+ (0.1 mM) buffer at 4°C until use (06 h).
Whole cell voltage clamp. Whole cell VGCC currents were determined using a standard voltage-clamp technique (3, 5, 6, 18). Cells were initially superfused with physiological saline solution (PSS) containing (in mM) 0.1 CaCl2, 138 NaCl, 1 MgCl2, 5 KCl, 10 HEPES, and 10 glucose, pH 7.4, during gigaseal formation. After whole cell configuration, the superfusate was switched to PSS with tetraethylammonium chloride substitution for NaCl and 10 mM Ba2+ as the charge carrier. The pipette solution contained (in mM) 120 CsCl, 10 tetraethylammonium chloride, 1 MgCl2, 20 HEPES, 5 Na2ATP, 0.5 Tris GTP, and 10 EGTA, pH 7.1. Ionic currents were amplified with an Axopatch 200B patch-clamp amplifier (Axon Instruments). Whole cell currents were low-pass filtered with a cutoff frequency of 1,000 Hz, digitized at 2.5 kHz, and stored on computer. Current densities (pA/pF) were obtained for each cell by normalization of whole cell current to cell capacitance to account for differences in cell membrane surface area. Capacity currents were measured for each cell during 10-ms pulses from a holding potential of 80 mV to a test potential of 75 mV. Capacity currents were filtered at a low-pass cutoff frequency of 5 kHz. Leak subtraction was not performed. Data acquisition and analysis were accomplished with the use of pCLAMP 7.0 software (Axon Instruments). Voltage-dependent activation was determined as g/gmax = peak IBa/[gBa(V Erev)], where gBa is the maximal conductance obtained from the linear regression of the positive limb of the current-voltage relationship through the apparent reversal potential (Erev), V is the step potential, and IBa is the peak inward current at the corresponding step potential. Activation data were fit to a conventional Boltzmann distribution equation, 1/{1 + exp[(V0.5 V)/k]}, where V0.5 is the membrane potential producing half-maximal activation and k is the slope factor. For voltage-dependent inactivation, peak inward current during a 500-ms step depolarization to +20 mV was determined after a 4-s prepulse at membrane potentials from 80 to +50 mV in 10-mV increments. Relative peak current (I/Imax) data were fit to a conventional Boltzmann distribution equation, 1/{1 + exp[(V0.5 V)/k]}. All experiments were conducted at room temperature (2225°C).
Immunoblot.
RCA segments (5 mm axial length) were quick frozen in liquid N2 and stored at 80°C until processed. Samples were minced thoroughly in 200 µl of ice-cold buffer (50 mM Tris·HCl, pH 7.4, 0.1 mM EDTA, 0.1 mM EGTA, 0.1%
-mercaptoethanol, 1 mM PMSF, 2 mM leupeptin, 1 mM pepstatin A, 10% vol/vol glycerol) and subjected to 4 x 30 s homogenizations at a speed of 4.05.0 using a FASTPREP 120 system (QBiogene) with samples kept on ice for 5 min between each pulse. After a low-speed centrifugation, supernatants were subjected to high-speed centrifugation (100,000 g for 1 h). Crude membrane pellets were dissolved by vortexing in homogenization buffer containing 0.1% Triton X-100 at room temperature. Membrane protein concentrations (35 µg/µl) were determined using a Bradford protein assay kit (Bio-Rad). Equal protein amounts (30 µg) of sample were electrophoresed on 5% SDS-polyacrylamide gels and transferred to a polyvinylidene difluoride membrane at 30 V for 1416 h at 4°C. After transfer, membranes were blocked for 1 h in Tris-buffered saline solution containing 5% dry milk plus 0.1% Tween 20 and probed with anti-Cav1.2 antibody (1:200; Alomone) for 2 h at room temperature. Immunoreactive bands were detected by chemiluminescence (ECL, Amersham) and quantified using NIH Image J software.
Quantitative RT-PCR.
Quantitative RT-PCR for Cav1.2 was performed as previously described (4) with modification. After dissection at 4°C, RCA segments (10 mm axial length) were quick frozen in RNase-free tubes for storage at 80°C until analysis. Frozen samples were powdered under liquid N2, and total RNA was extracted (TRI Reagent, Molecular Research Center). cDNA was transcribed from total RNA using the Superscript II RT kit (Invitrogen) using 200 units of RT in a 20-µl reaction containing 100 ng random hexamers, 5 mM MgCl2, 1 mM dNTPs, and 20 mM DTT. A minus RT reaction was performed to ensure no genomic DNA contamination. Quantitative RT-PCR was performed with the use of Texas red-labeled probes (IDT) on a Smart Cycler (model no. SC1000-1, Cepheid). The 25-µl reaction mixture contained RT buffer (Invitrogen), BHQ-2 quencher, 5 mM MgCl2, 0.8 mM dNTPs, 0.8 µM primer/probe, and 1 unit Taq polymerase (Roche). Each primer set was optimized for cycle time, annealing temperature, and MgCl2 concentration. Each PCR reaction was initiated by a 5-min incubation at 95°C. Cav1.2 was amplified using 40 cycles of 95°C (15 s), 60°C (30 s), and 72°C (30 s). 18S was amplified using 40 cycles of 95°C (15 s) and 60°C (1 min). The primer sets were the following: Cav1.2 sense, 5'-GTG TTC CAG TGT ATC ACC ATG G-3'; antisense, 5'-GTT GAC AGA TTC GGT CTC ACT TG-3'; and probe 5'-GGA CGA GGA GAA GCC CCG AA-3'; 18S sense, 5'-CGG CTA CCA CAT CCA AGG AA-3'; antisense, 5'-AGC TGG AAT TAC CGC GGC-3'; and probe, 5'-TGC TGG CAC CAG ACT TGC CCT C-3'. Nucleotide sequencing confirmed amplification of the expected product and demonstrated complete homology between human and Yucatan porcine Cav1.2 PCR-amplified products. Cav1.2 mRNA expression was normalized to 18S using the 2
C
method (29), where the threshold cycle difference (
Ct) is determined as CtCav12 Ct18S. Efficiency of the PCR reaction was verified by generating a standard curve-plotting Ct against serial dilutions of cDNA. A replication efficiency near 1.0 was determined by linear regression fit of the standard curve.
Immunohistochemistry. Androgen receptor (AR) expressions were determined using a standard immunohistochemistry protocol as used routinely (4). Samples of RCA were fixed in neutral buffered 10% formalin for a minimum of 24 h, embedded routinely in paraffin, and sectioned serially at 5 µm thickness. Sections were floated onto positively charged slides (Fischer), deparaffinized, and steamed in citrate buffer at pH 6.0 (Dako S1699) for 30 min to achieve antigen retrieval and then cooled for 30 min. The slides were stained manually with Tris buffer or water wash steps performed after each step. Sections were incubated with avidin-biotin two-step blocking solution (Vector SP-2001) to inhibit background staining and in 3% hydrogen peroxide to inhibit endogenous peroxidase. Nonserum protein block (Dako X909) was applied to inhibit nonspecific protein binding. Sections were incubated overnight at 4°C with a 1:800 dilution of primary rabbit polyclonal antibodies to AR (Affinity Bioreagents). After the appropriate washing steps were made, sections were incubated with biotinylated anti-rabbit secondary antibody in PBS containing 15 mM sodium azide and peroxidase-labeled streptavidin (Dako LSAB+ kit, peroxidase, K0690). Diaminobenzidine (Dako) was applied for 5 min to visualization of the reaction product. Sections were counterstained with Mayer's hematoxylin stain for 1 min, dehydrated, and coverslipped. Sections were photographed with an Olympus BX40 photomicroscope and Spot Insight Color camera (Diagnostic Instruments).
Statistics.
Data are expressed as means ± SE. Repeated-measures ANOVA was used for comparisons of current-voltage (I-V) relationships between groups. All other comparisons were made by ANOVA. Bonferroni post hoc analyses were applied when significant main or interaction effects were determined. A P value
0.05 was set as the criterion for significance in all comparisons.
| RESULTS |
|---|
|
|
|---|
|
|
|
|
50% greater Cav1.2 mRNA compared with intact females. Castration markedly reduced Cav1.2 mRNA levels in males, whereas testosterone prevented the loss of mRNA due to castration. Similarly, Cav1.2 protein levels were greater in males compared with females (Fig. 6A). This sex difference was eliminated by castration and prevented by testosterone. These in vivo effects of testosterone could be replicated in vitro. Coronary arterial segments were incubated in phenol-free RPMI culture media in a 37°C, humidified culture chamber for 18 h in the presence or absence of testosterone or dihydrotestosterone (DHT). Both testosterone and DHT produced similar increases in Cav1.2 protein (Fig. 6B). In addition, both testosterone (100 nM) and DHT (100 nM) produced an approximately twofold increase in Cav1.2 mRNA (2.0 ± 0.4 and 2.5 ± 0.5, respectively; P < 0.05). Dihydrotestosterone is a nonaromatizable androgen produced by conversion from testosterone by 5-
reductase that binds the AR. The similar effect of testosterone and DHT on Cav1.2 protein levels indicates that aromatization of testosterone to estrogen is not necessary for the observed effects of testosterone.
|
|
|
| DISCUSSION |
|---|
|
|
|---|
Although numerous studies have examined acute effects of sex hormones on vascular function (9, 11, 3840, 44), there is a paucity of information regarding long-term vascular effects of testosterone. Khalil and colleagues (9, 10, 34) provided convincing, yet indirect, evidence that gender differences in vascular reactivity between males and females is due to sex differences in VGCC activity. Crews et al. (10) reported depolarization-induced contraction and Ca2+ influx was greater in thoracic aortas of male rats compared with females. This difference was eliminated by ovariectomy in females and restored with estrogen replacement. Importantly, castration in male rats had no effect. On the basis of these data, it was concluded that estrogen is the primary sex hormone modulating depolarization-induced Ca2+ influx in vascular smooth muscle, in part by reducing VGCC activity. In rodents, this conclusion is supported by reports of increased expression of L-type VGCCs in estrogen-receptor null mice (21). However, our data clearly indicate that in a large mammal model, endogenous testosterone is a potent stimulator of L-type VGCC expression and activity in CASM. Endogenous testosterone increased L-type VGCC mRNA, protein and channel activity, which contributes substantially to sex differences in CASM ICa,L (3). Elimination of gonadal testosterone production in males by castration reduced endogenous serum testosterone, CASM ICa, and Cav1.2 protein to levels similar to that in females, an effect that was prevented by exogenous testosterone. This is in agreement with other large mammal studies, where KCl responses of left anteriod descending coronary artery segments were increased in both male and female swine administered testosterone subcutaneously for 2 wk (12) and a trend for increased KCl-induced contractions in coronary arteries from adult swine compared with prepubescent swine (7). In addition, canine coronary artery contractions to U46619 [GenBank] are increased in males compared with females, a difference eliminated by antiandrogens (24). Thus data obtained in large mammal models support testosterone as a primary mediator of L-type VGCC synthesis in CASM. The long-term genomic effect of circulating testosterone is interesting in light of recent findings that nanomolar levels of testosterone produce acute, rapid and presumably nongenomic inhibition of L-type VGCC activity (38). It is possible that the long-term, genomic upregulation of Cav1.2 is a compensatory mechanism for nongenomic inhibition of L-type channel activity by testosterone. At this point, the net effect of genomic and nongenomic actions of testosterone on calcium influx via L-type Ca2+ channels in vivo is unknown.
While testosterone appears to be a primary determinant of coronary L-VGCC expression and activity in males, factors other than serum testosterone appear to influence L-VGCC activity in females (Fig. 4). This conclusion is based on the finding that, whereas a strong, linear relationship between serum testosterone levels and CASM ICa was observed in males, serum testosterone was not a good predictor of CASM ICa in intact females (Fig. 4). Other factors, e.g., estrogen or progesterone, may influence coronary L-type VGCC activity in females. This is also evident by the Cav1.2 mRNA levels in females, which are higher than predicted based on serum testosterone levels alone.
L-type VGCC are heteromeric complexes minimally composed of three protein subunits,
1,
2/
, and
. Cav1.2 forms the channel pore (20) and contains the binding sites for dihydropyridine antagonists (42). Testosterone increased Cav1.2 mRNA and protein levels suggesting a stimulation of translational and transcriptional activity of the Cav1.2 gene. The 5'-untranslated region of the
-subunit of the L-type VGCC (Cav1.2) gene contains a putative hormone response element and is activated by testosterone in both cardiac and smooth muscle cells in vitro (27). Similarly, castration has been shown to reduce cardiac Cav1.2 mRNA levels, an effect prevented by testosterone treatment (14, 15). Although we did not measure mRNA synthesis or degradation rates, our quantitative RT-PCR data support a role for testosterone in transcriptional regulation of Cav1.2 in CASM. Interestingly, the relative loss of Cav1.2 mRNA in the CM group was greater than that of Cav1.2 protein or ICa. One plausible explanation may be that the loss of mRNA on testosterone removal is rapid, whereas channel protein turnover is much slower. Others have shown dramatic reductions in cardiac Cav1.2 mRNA 2 wk after castration in rats (14). In the present study, animals were studied 5 wk after castration, a time sufficient for a dramatic reduction in Cav1.2 mRNA. Longer periods of testosterone deficiency may be necessary for channel protein levels to reach a nadir.
Testosterone has been described as exerting both genomic and nongenomic actions. Classic genomic actions are mediated through the intracellular AR, a 110-kDa protein with domains for androgen binding, DNA binding, and transactivation (28). Conversely, rapid, acute, nongenomic actions of testosterone (38) are thought to be mediated by membrane ARs on cell surfaces (28). In addition, testosterone can also be converted to estrogen via vascular aromatase and exert its action through estrogen receptors (33, 35). Vascular smooth muscles, including CASM, express estrogen receptors and ARs (19, 25), a finding confirmed in CASM by this study (Fig. 7A). Thus endogenous testosterone could influence coronary calcium channels through numerous mechanisms. Evidence in this study indicates that testosterone increases Cav1.2 gene expression in CASM through a genomic AR-mediated mechanism. Specifically, 1) testosterone increased Cav1.2 mRNA and protein, 2) the effect of testosterone was blocked by an AR antagonist, and 3) aromatization of testosterone to estrogen was not necessary for these effects as dihydrotestosterone produced responses similar to testosterone.
In conclusion, our data demonstrate that endogenous testosterone is a primary modulator of L-type calcium channel synthesis and activity in CASM. Sex differences in several candidate mechanisms impacting cardiovascular disease have been reported, including nitric oxide synthase content and nitric oxide production (26), smooth muscle proliferation (32), and smooth muscle responsiveness to agonists (34). L-type VGCCs play a central role in regulation of vascular tone (36) and have been proposed to contribute to the incidence and severity of both acute and long-term cardiovascular events, such as vasospasm and coronary heart disease (22, 31). Thus increased expression and activity of L-type VGCCs in coronary arterial smooth muscle by testosterone provides a potential mechanism for sex differences in coronary vasoreactivity and pathology.
| GRANTS |
|---|
|
|
|---|
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
| REFERENCES |
|---|
|
|
|---|

CT method. Methods 25: 402408, 2001.[CrossRef][ISI][Medline]
-subunit. Science 285: 19291931, 1999.This article has been cited by other articles:
![]() |
D.L. Tharp, B.R. Wamhoff, H. Wulff, G. Raman, A. Cheong, and D.K. Bowles Local Delivery of the KCa3.1 Blocker, TRAM-34, Prevents Acute Angioplasty-Induced Coronary Smooth Muscle Phenotypic Modulation and Limits Stenosis Arterioscler. Thromb. Vasc. Biol., June 1, 2008; 28(6): 1084 - 1089. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Burnes, S. J. Kolker, J. F. Danielson, R. Y. Walder, and K. A. Sluka Enhanced muscle fatigue occurs in male but not female ASIC3-/- mice Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2008; 294(4): R1347 - R1355. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. K. Bowles, K. K. Maddali, V. C. Dhulipala, and D. H. Korzick PKC{delta} mediates anti-proliferative, pro-apoptic effects of testosterone on coronary smooth muscle Am J Physiol Cell Physiol, August 1, 2007; 293(2): C805 - C813. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. L. Tharp, B. R. Wamhoff, J. R. Turk, and D. K. Bowles Upregulation of intermediate-conductance Ca2+-activated K+ channel (IKCa1) mediates phenotypic modulation of coronary smooth muscle Am J Physiol Heart Circ Physiol, November 1, 2006; 291(5): H2493 - H2503. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |